Introduction
============

The prevalence of chronic obstructive pulmonary disease (COPD) is increasing with the aging of society.[@b1-copd-5-233],[@b2-copd-5-233] Cigarette smoking and advanced age are risk factors for COPD,[@b3-copd-5-233] which not only decreases individual quality of life (QOL),[@b4-copd-5-233] but it also imposes a high burden of medical cost on the economy.[@b1-copd-5-233] Although the Global Initiative for Chronic Obstructive Lung Disease defines COPD as a preventable and treatable disease,[@b3-copd-5-233] prevention is obviously much more important than treatment.

COPD is now recognized as a systemic disease.[@b5-copd-5-233] One of the systemic effects of COPD is the presence of nutritional abnormalities that causes body weight loss.[@b5-copd-5-233] Approximately 50% of patients with severe COPD and 10% to 15% of those in the mild to moderate stage suffer body weight loss, possibly due to hypermetabolism.[@b6-copd-5-233] Decreases in body weight,[@b7-copd-5-233] body mass index (BMI),[@b8-copd-5-233],[@b9-copd-5-233] and fat-free mass index[@b9-copd-5-233] have been reported to be associated with mortality in patients with COPD. In this context, many clinical studies have investigated the efficacy of nutritional support for patients with COPD, which, however, remains controversial. A meta-analysis by Ferreira et al indicated that nutritional support had no significant effect on anthropometric measures in patients with stable COPD.[@b10-copd-5-233] This suggests that nutritional support for COPD patients to maintain healthy body weight and composition is difficult. Moreover, COPD patients tend to have nutrition-related comorbidities such as diabetes and anemia,[@b11-copd-5-233] implying that patients with COPD likely have impaired metabolism or nutritional abnormalities. However, little is known about the association between lung function and nutritional status in those with risk factors for COPD, such as cigarette smoking and advanced age, but not falling under the category of COPD. Knowledge of this association is expected to be useful in the prevention of COPD.

In the present study, we tested the hypothesis that reduced lung function is associated with lower blood markers of nutritional status in non-COPD aging men with smoking history. In addition to an urgent need to prevent COPD, the fact that the cut-off point for COPD -- forced expiratory volume in one second (FEV~1~) as percent of forced vital capacity (FVC) (FEV~1~/FVC) \< 70% -- has been used for pragmatic simplicity[@b12-copd-5-233] without adequate medical evidence to support it[@b13-copd-5-233] seems to justify the necessity of the present study.

Subjects and methods
====================

Study design
------------

This cross-sectional study examined the association between lung function and blood markers of nutritional status in non-COPD aging men with smoking history. Each eligible subject was asked to visit Okayama University Hospital Misasa Medical Center three times during the study. At the first visit, written informed consent was obtained; at the second visit, anthropometric measurements, blood sampling, and spirometry testing were conducted, followed by distribution of in-home, self-administered questionnaires on diet and lifestyle; and at the third visit, the completed questionnaires were collected and detailed interviews carried out by a registered dietician about their answers. The protocol of the present study was approved by the Ethics Committee of the Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University.

Subjects
--------

Male current or former smokers aged 50 to 80 years were recruited in one of the following two ways: recruitment of COPD outpatients at Okayama University Hospital Misasa Medical Center or recruitment of those who had never been diagnosed with COPD and participated in a health promotion program in a rural town in Tottori Prefecture, located in the western part of Japan. The exclusion criteria were: 1) those who had been given dietary advice by medical staff (eg, physician or registered dietician) and confirmed that they were in compliance with the advice; 2) those taking drugs for hyperlipidemia, hyperglycemia, or diabetes; and 3) those who had suffered from a COPD exacerbation within the previous month.

Anthropometric, blood, and lung function measurements
-----------------------------------------------------

At the second visit, each subject arrived at Okayama University Hospital Misasa Medical Center between 08:30 and 10:00 AM after overnight fasting. After measurements of height and abdominal circumference at the level of the umbilicus, body weight, BMI, and percent of body muscle were measured with a body composition analyser (DF860K, Yamato Scale Co., Ltd., Akashi, Hyogo, Japan) using the bioelectrical impedance analysis method. Then, fasting blood was drawn from an antecubital vein in a sitting position for determining red blood cell count (RBCc), white blood cell count (WBCc), and levels of hemoglobin (Hb), hematocrit, total protein (TP), albumin, triglyceride, total cholesterol (TC), LDL-cholesterol (LDL-c), HDL-cholesterol (HDL-c), glucose, and HbA1c. The concentrations of the blood components listed above were measured using automatic analysers: XT-2000i (Sysmex America Inc., Mundelein, IL, USA) for RBCc, WBCc, Hb, and hematocrit; and Dimension^®^ Xpand^®^ (Siemens Healthcare Diagnostics Inc., Deerfield, IL, USA) for TP, albumin, triglyceride, TC, LDL-c, HDL-c, glucose, and HbA1c. Anthropometric measurements and blood sampling were conducted by nurses. After blood sampling, spirometry testing was performed by a well-trained clinical technologist to assess FEV~1~/FVC and predicted forced expiratory volume in one second (FEV~1~% pred) according to the COPD guidelines of The Japan Respiratory Society 2004.[@b14-copd-5-233] Subjects never before diagnosed with COPD underwent spirometry testing without a bronchodilator. Both the subjects with FEV~1~/FVC \< 70% at the first test and COPD outpatients were asked to inhale 200 μg of salbutamol according to pharmacists' instructions to avoid the effects of airway reversibility; 30 min after inhalation, spirometry testing was performed. Those with FEV~1~/FVC \< 70% after bronchodilator administration were diagnosed with COPD. For subjects who inhaled salbutamol, post-bronchodilator values were used for data analysis.

Dietary assessment
------------------

Food and nutrient consumption was calculated using Excel Eiyo-kun FFQg software (version 2.0; Kenpakusha, Tokyo, Japan), a semiquantitative food frequency questionnaire based on the fifth revised and enlarged edition of the Standard Tables of Food Composition in Japan. The respondents were asked about their usual dietary intake per week for the previous month. Dietary interviews were conducted by registered dieticians using food models in order to increase the precision of the dietary intake estimate.

Lifestyle questionnaire
-----------------------

In the lifestyle questionnaire, subjects were asked about their medical history, medication use, smoking status, pack-years, and history of occupational dust exposure. To estimate pack-years as precisely as possible, original graph paper sheets (95 × 140 mm) were prepared with the X-axis indicating age (10 to 85 years, at 5-year intervals) and the Y-axis indicating the number of cigarettes smoked per day at each age (0 to 100 cigarettes, at intervals of 10 cigarettes). During the interview, subjects were asked about their graphs, and where necessary, age and the number of cigarettes were corrected. Then, pack-years were calculated from the graph using the trapezoidal method, and the duration of the current period of smoking cessation was obtained.

Statistical analysis
--------------------

First, subjects were assigned to the COPD group (the reference group) or the non-COPD group, and the non-COPD group was then divided into groups according to FEV~1~/FVC results so that each group contained approximately the same number of subjects as the COPD group. The subjects' characteristics are presented as means ± standard deviation (SD) or percent. Values of blood test results and dietary intake in each subject group were expressed as adjusted means or geometric means and 95% confidence intervals, using analysis of covariance (ANCOVA). Tests for linear trend across subject groups were performed by treating FEV~1~/FVC as a continuous variable in multiple linear regression analyses. In ANCOVAs and multiple linear regression analyses, the following potential confounders were considered and included: age, BMI, percent of body muscle, total energy intake (kcal·day^−1^), pack-years, pack-years squared, current duration of smoking cessation (years), and history of occupational dust exposure (\<1 year or ≥1 year). Variables that showed an extremely skewed distribution were transformed to natural logarithms (ln) (ln(X) or ln(X +1)) for data analysis and then back-transformed to the original values. Statistical analysis was performed using SPSS version 16.0 J for Windows (SPSS Inc., Chicago, IL, USA), and a *P*-value \<0.05 (two-sided) was considered statistically significant.

Results
=======

Written informed consent was obtained from 74 men. Of these, 3 dropped out, and 6 were excluded because of their healthier diet as advised by the medical staff (n = 5), and drinking juice just before blood drawing (n = 1). Therefore, 65 subjects were included in the study ([Figure 1](#f1-copd-5-233){ref-type="fig"}).

Of these subjects, 17 were in the COPD group and 48 were in the non-COPD group. The distribution of the disease severity in the COPD group was as follows: 3 men with mild; 9 with moderate; 4 with severe; and 1 with very severe disease. The non-COPD group was divided into tertiles (non-T3, top; non-T2, middle; non-T1, bottom tertile) according to FEV~1~/FVC level for data analysis ([Table 1](#t1-copd-5-233){ref-type="table"}).

[Table 2](#t2-copd-5-233){ref-type="table"} describes each group's characteristics. The subjects with lower FEV~1~/FVC tended to be older and to have lower height, weight, and BMI. The COPD group apparently had lower body muscle and total energy intake. The non-T1 and COPD groups had a greater number of pack-years and longer histories of occupational dust exposure than the non-T3 and non-T2 groups.

[Table 3](#t3-copd-5-233){ref-type="table"} shows the blood results for each group adjusted for potential confounders. Lower FEV~1~/FVC was significantly associated with lower RBCc, Hb, hematocrit, and TP, which are markers of anemia and nutritional status, in all adjusted models. RBCc and TP decreased by approximately 5% to 6% between non-T3 and non-T1; this difference was larger than that observed between the non-T1 and COPD groups. Albumin showed a similar trend to RBCc and TP, but it was not statistically significant after adjustment for all potential confounders, including smoking variables and history of occupational dust exposure. In relation to fat metabolism, LDL-c was significantly lower with decreased FEV~1~/FVC in all adjusted models. There was a similar decreasing trend for TC, but it was not statistically significant after adjustment for age, BMI, percent of body muscle, and total energy intake. FEV~1~/FVC showed no association with glucose and HbA1c, which were similar across subject groups.

[Table 4](#t4-copd-5-233){ref-type="table"} shows the adjusted dietary intake for each group. FEV~1~/FVC was not associated with intake of total energy, protein, fat, or carbohydrate. However, iron intake tended to increase as FEV~1~/FVC decreases after adjustment for age, BMI, percent of body muscle, and energy intake. Moreover, the inverse association of FEV~1~/FVC with iron intake remained strong after further adjustment for smoking variables and history of occupational dust exposure. Although cholesterol intake showed a similar trend to that of iron, it was not statistically significant.

Discussion
==========

The present study investigated a potential association between lung function and blood markers of nutritional status in male current or former smokers. This study was unique in that non-COPD subjects were categorized into three groups based on FEV~1~/FVC tertiles. In contrast, most previous studies in this field simply compared the COPD group with the non-COPD group without further dividing the subjects with non-COPD into groups. COPD is now defined as a preventable disease;[@b3-copd-5-233] therefore, from the perspective of prevention, it is important to focus on those with risk factors such as smoking history and advanced age but who do not fulfil the COPD diagnostic criteria, especially men with an FEV~1~/FVC close to 70%.

Our main results were as follows: (1) lower FEV~1~/FVC was linearly associated with lower RBCc, Hb, hematocrit, TP, and LDL-c after adjustments for all potential confounders; (2) FEV~1~/FVC was not associated with intake of total energy, protein, fat, carbohydrate, or cholesterol. Together, these results support our hypothesis that reduced lung function is associated with reduced nutritional status in non-COPD aging men with smoking history. This suggests that in those men, trends toward reduced nutritional status and anemia may emerge independently as changes in blood test results, along with decreased lung function, even before the onset of COPD.

TP and albumin are markers of nutritional status.[@b15-copd-5-233] In the present study, FEV~1~/FVC was linearly associated with TP in all adjusted models, and the decrease in adjusted TP between the non-T3 and non-T1 groups was larger than that between the non-T1 and COPD groups. Nevertheless, FEV~1~/FVC was not associated with adjusted intake of total energy and nutrients, except iron. To the best of our knowledge, this is the first study to report that decreasing degree of TP in non-COPD aging men with smoking history could be comparable to or greater than that in COPD patients. In contrast to TP, the association between albumin and FEV~1~/FVC was slight. One possible explanation for this is that albumin is pooled in the extravascular space and is then mobilized to the intravascular space as needed with its degradation rate decreasing, which allows a relatively constant blood level to be maintained.[@b16-copd-5-233]--[@b18-copd-5-233]

COPD has been reported to be associated with anemia,[@b19-copd-5-233],[@b20-copd-5-233] which is causally related to dyspnoea, reduced exercise capacity,[@b21-copd-5-233] and health-related QOL.[@b22-copd-5-233] The mechanism of COPD is believed to be similar to that of other chronic diseases. In patients with chronic diseases, elevated levels of inflammatory cytokines could shorten RBC survival, impair mobilization or utilization of iron, and impair the marrow erythropoietic response.[@b19-copd-5-233],[@b23-copd-5-233] In the present study, lower FEV~1~/FVC was linearly associated with lower RBCc, Hb, and hematocrit after adjustments for all potential confounders. In contrast, FEV~1~/FVC was inversely associated with adjusted iron intake; subjects with a lower FEV~1~/FVC had a greater iron intake. These findings suggest that RBC dysregulation, in which impaired utilization of iron is implicated, could occur in male current or former smokers as FEV~1~/FVC decreases even before the onset of COPD. It has been shown that cigarette smoking alters iron homeostasis, greatly increases lung iron concentration, and generates oxidative stress and inflammation,[@b24-copd-5-233] which may increase the iron requirement. A meta-analysis by Gan et al indicated that WBCc may be a useful marker of systemic inflammation in COPD patients.[@b25-copd-5-233] Van Hoydonck et al reported that male current smokers and female current or former smokers had greater iron intake than male former smokers and female never smokers, respectively.[@b26-copd-5-233] In the present study, WBCc and iron intake in the non-T1 and COPD groups were greater than those in the non-T3 and non-T2 groups, implying that there is an association between inflammation and iron requirement in male current or former smokers, even before the onset of COPD. In the present study, the levels of anemia markers in each subject group were all within the normal range, which can be explained as follows: first, the prevalence of anemia is actually not very high, even in COPD patients. In a cross-sectional study by John et al,[@b20-copd-5-233] the prevalence of anemia in COPD patients was 13%, and that in a retrospective study by Cote et al[@b21-copd-5-233] was 17%. Second, three-fourths of the subjects in the present study were in the non-COPD group. Further studies focusing on associations between FEV~1~/FVC and serum iron, transferrin, ferritin, transferrin receptor, and inflammatory cytokines in male current or former smokers with non-COPD are needed.

Although several previous studies have reported an association between lung function and diabetes,[@b27-copd-5-233] most used FEV~1~ or FVC, not FEV~1~/FVC, as markers of lung function, which seems to be insufficient to evaluate whether chronic airflow obstruction is related to glucose metabolism. In the present study, FEV~1~/FVC was not associated with glucose or HbA1c, suggesting that chronic airflow obstruction is not independently associated with glucose control. The present result was consistent with that of a large prospective study by Ford et al,[@b28-copd-5-233] in which FEV~1~, FVC, and FEV~1~% pred were significantly negatively associated with the incidence of diabetes, whereas FEV~1~/FVC was not. In the present study, subjects who took drugs for hyperglycemia or diabetes were excluded so that medication use did not mask impaired glucose control, which may also result in the disassociation of FEV~1~/FVC with glucose and HbA1c.

The present study had several limitations. First, we cannot completely rule out the possibility of chance due to relatively small sample size. In spite of the relatively small sample size, however, it was noted that lower FEV~1~/FVC was significantly associated with lower TP and Hb, and future studies are warranted to confirm these results in larger samples. Second, while it is essential to consider physical activity for nutritional assessment, the data on physical activity was not available in the present study; this may somewhat confound associations between FEV~1~/FVC and nutritional markers. Although it has been reported that men with COPD have elevated resting energy expenditure[@b29-copd-5-233],[@b30-copd-5-233] or daily activity energy expenditure,[@b31-copd-5-233],[@b32-copd-5-233] most subjects had relatively high FEV~1~/FVC, and it is less likely that the present findings are fully explained by the residual confounding. Although it remains unknown whether energy expenditure tended to be elevated among men whose FEV~1~/FVC fell close to 70%, future studies should aim to reduce the confounding due to physical activity by measuring resting energy expenditure and daily activity energy expenditure.

In summary, the present study shows that lower FEV~1~/FVC is independently linearly associated with lower blood markers of nutritional status and anemia. The present results suggest that, in non-COPD aging men with smoking history, slight but significant trends toward reduced nutritional status and anemia may emerge along with decreased lung function even before the onset of COPD. Further studies are needed to examine the mechanism by which disease progression occurs in current or former smokers with non-COPD.
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**Abbreviations:** COPD, chronic obstructive pulmonary disease; FEV~1~/FVC, forced expiratory volume in one second as percent of forced vital cavity; T, tertile.](copd-5-233f1){#f1-copd-5-233}

###### 

Classification of subjects according to FEV~1~/FVC

                   **Subjects n**   **FEV~1~/FVC %**   
  ---------------- ---------------- ------------------ -------------
  Non-COPD group                                       
    Non-T3         16               78.9 to 85.4       81.5 ± 2.4
    Non-T2         16               73.5 to 78.7       75.7 ± 1.7
    Non-T1         16               70.1 to 73.3       71.9 ± 1.1
  COPD group       17               31.0 to 67.7       52.4 ± 11.0

**Abbreviations:** COPD, chronic obstructive pulmonary disease; FEV~1~/FVC, forced expiratory volume in one second as percent of forced vital cavity; T, tertile.

###### 

Subjects' characteristics

                                                                      **Non-COPD group**   **COPD group**                
  ------------------------------------------------------------------- -------------------- ---------------- ------------ ------------
  Subjects (n)                                                        16                   16               16           17
  Age (yrs)                                                           60 ± 6               60 ± 7           65 ± 6       70 ± 7
  Height (cm)                                                         169 ± 7              169 ± 3          164 ± 5      165 ± 7
  Weight (kg)                                                         69 ± 10              63 ± 7           60 ± 9       60 ± 7
  BMI (kg·m^−2^)                                                      24.1 ± 2.2           22.2 ± 2.3       22.2 ± 2.8   22.1 ± 2.7
  Body muscle (%)                                                     32 ± 3               33 ± 2           32 ± 3       30 ± 5
  Body fat (%)                                                        24 ± 5               21 ± 6           20 ± 7       23 ± 7
  Abdominal circumference (cm)                                        87 ± 6               83 ± 7           82 ± 9       84 ± 8
  Total energy intake (kcal·d ^−1^)                                   2137 ± 260           2148 ± 414       2206 ± 545   1927 ± 490
  Smoking status                                                                                                         
    Current smoker (n)                                                7 (44)               7 (44)           9 (56)       5 (29)
    Former smoker (n)                                                 9 (56)               9 (56)           7 (44)       12 (71)
      Current duration of smoking cessation in former smokers (yrs)   6.9 ± 5.3            14.4 ± 10.9      8.7 ± 6.7    10.8 ± 9.2
  Pack-years                                                          45 ± 13              32 ± 19          53 ± 18      52 ± 32
  History of occupational dust exposure ≥1 year (n)                   1 (6)                4 (25)           7 (44)       7 (41)

**Notes:** Data are presented as mean ± SD, n or n (%).

**Abbreviations:** BMI, body mass index; COPD, chronic obstructive pulmonary disease; T, tertile.

###### 

Association between FEV~1~/FVC and adjusted blood components

                                                                                  **Non-COPD group**   **COPD group**   ***P*-value**[¶](#tfn6-copd-5-233){ref-type="table-fn"}                                                              
  --------------------------------------------------------------------- --------- -------------------- ---------------- --------------------------------------------------------- -------------- ------ -------------- ------ -------------- ---------
  RBC (10^6^·μl^−1^)                                                    Model 1   4.94                 4.77 to 5.10     4.81                                                      4.65 to 4.98   4.64   4.48 to 4.80   4.52   4.36 to 4.69   \<0.001
                                                                        Model 2   4.93                 4.76 to 5.09     4.83                                                      4.67 to 4.99   4.62   4.47 to 4.78   4.54   4.37 to 4.70   \<0.001
                                                                        Model 3   4.96                 4.79 to 5.13     4.80                                                      4.63 to 4.97   4.64   4.48 to 4.80   4.52   4.35 to 4.69   \<0.001
  WBC (10^3^·μl^−1^)                                                    Model 1   5.77                 4.92 to 6.61     5.39                                                      4.54 to 6.23   6.63   5.81 to 7.45   6.69   5.82 to 7.56   0.075
                                                                        Model 2   5.66                 4.78 to 6.54     5.41                                                      4.55 to 6.26   6.73   5.90 to 7.56   6.68   5.79 to 7.57   0.051
                                                                        Model 3   5.66                 4.77 to 6.55     5.54                                                      4.65 to 6.43   6.68   5.83 to 7.52   6.60   5.72 to 7.48   0.081
  Hb (g·dl^−1^)                                                         Model 1   15.2                 14.8 to 15.7     15.0                                                      14.6 to 15.4   14.9   14.5 to 15.3   14.3   13.9 to 14.8   0.014
                                                                        Model 2   15.2                 14.8 to 15.7     15.0                                                      14.6 to 15.5   14.9   14.5 to 15.3   14.3   13.9 to 14.8   0.013
                                                                        Model 3   15.4                 14.9 to 15.8     15.0                                                      14.5 to 15.5   14.9   14.4 to 15.3   14.2   13.8 to 14.7   0.003
  Hematocrit (%)                                                        Model 1   46.7                 45.4 to 47.9     46.2                                                      44.9 to 47.4   45.7   44.5 to 46.9   44.0   42.7 to 45.3   0.008
                                                                        Model 2   46.7                 45.4 to 48.0     46.2                                                      45.0 to 47.5   45.6   44.4 to 46.8   44.0   42.7 to 45.3   0.008
                                                                        Model 3   47.1                 45.7 to 48.4     46.2                                                      44.9 to 47.5   45.5   44.3 to 46.8   43.8   42.5 to 45.1   0.002
  TP (g·dl^−1^)                                                         Model 1   7.9                  7.7 to 8.1       7.7                                                       7.4 to 7.9     7.5    7.3 to 7.7     7.4    7.2 to 7.6     \<0.001
                                                                        Model 2   7.9                  7.7 to 8.1       7.7                                                       7.5 to 7.9     7.5    7.3 to 7.7     7.4    7.1 to 7.6     \<0.001
                                                                        Model 3   7.9                  7.7 to 8.2       7.7                                                       7.5 to 7.9     7.5    7.3 to 7.7     7.3    7.1 to 7.6     \<0.001
  Albumin (g·dl^−1^)[\#](#tfn5-copd-5-233){ref-type="table-fn"}         Model 1   4.2                  4.0 to 4.3       4.1                                                       4.0 to 4.2     4.1    4.0 to 4.2     4.0    3.8 to 4.1     0.032
                                                                        Model 2   4.2                  4.0 to 4.3       4.1                                                       4.0 to 4.2     4.1    3.9 to 4.2     4.0    3.8 to 4.1     0.036
                                                                        Model 3   4.2                  4.0 to 4.3       4.1                                                       4.0 to 4.3     4.1    3.9 to 4.2     4.0    3.8 to 4.1     0.066
  Trigryceride (mg·dl^−1^)[\#](#tfn5-copd-5-233){ref-type="table-fn"}   Model 1   154                  122 to 195       108                                                       85 to 137      120    96 to 151      115    90 to 147      0.139
                                                                        Model 2   141                  112 to 178       111                                                       89 to 139      121    97 to 150      121    96 to 153      0.462
                                                                        Model 3   143                  114 to 180       112                                                       89 to 140      121    97 to 150      119    95 to 149      0.366
  TC (mg·dl^−1^)                                                        Model 1   219                  204 to 235       205                                                       190 to 221     190    175 to 206     198    182 to 214     0.040
                                                                        Model 2   220                  203 to 236       204                                                       189 to 221     190    174 to 206     199    182 to 215     0.053
                                                                        Model 3   220                  203 to 238       208                                                       190 to 225     187    171 to 203     198    181 to 215     0.045
  LDL-c (mg·dl^−1^)                                                     Model 1   140                  125 to 155       121                                                       106 to 136     102    87 to 117      114    98 to 130      0.011
                                                                        Model 2   139                  123 to 155       121                                                       106 to 137     102    87 to 118      114    98 to 130      0.021
                                                                        Model 3   139                  123 to 155       127                                                       110 to 143     97     82 to 113      114    97 to 130      0.015
  HDL-c (mg·dl^−1^)                                                     Model 1   49                   44 to 55         56                                                        50 to 62       58     53 to 64       52     46 to 58       0.379
                                                                        Model 2   52                   46 to 58         55                                                        49 to 60       57     52 to 63       52     46 to 57       0.862
                                                                        Model 3   52                   46 to 58         53                                                        47 to 59       58     53 to 64       52     46 to 58       0.749
  Glucose (mg·dl^−1^)                                                   Model 1   102                  96 to 107        101                                                       96 to 106      103    98 to 108      101    96 to 107      0.956
                                                                        Model 2   100                  95 to 106        102                                                       97 to 107      104    99 to 109      101    96 to 107      0.637
                                                                        Model 3   100                  94 to 106        101                                                       96 to 107      104    99 to 109      102    96 to 107      0.597
  HbA1c (%)[\#](#tfn5-copd-5-233){ref-type="table-fn"}                  Model 1   5.4                  5.2 to 5.5       5.3                                                       5.2 to 5.5     5.3    5.2 to 5.5     5.4    5.3 to 5.6     0.797
                                                                        Model 2   5.4                  5.2 to 5.5       5.3                                                       5.2 to 5.5     5.3    5.2 to 5.5     5.4    5.2 to 5.6     0.718
                                                                        Model 3   5.4                  5.2 to 5.5       5.3                                                       5.2 to 5.5     5.3    5.2 to 5.5     5.4    5.2 to 5.6     0.762

**Notes:** Model 1, adjusted for age; Model 2, adjusted for age, body mass index, percent of body muscle, and total energy intake; Model 3, adjusted for all variables in Model 2 plus pack-years, pack-years squared, current-duration of smoking cessation, and history of occupational dust exposure ≥1 year;

log transformed for data analysis to improve normality, and back transformed to present data;

test for linear trend across groups was performed by treating FEV~1~/FVC as a continuous variable in multiple linear regression analysis.

**Abbreviations:** Adj, adjusted; COPD, chronic obstructive pulmonary disease; CI, confidence interval; FEV~1~/FVC, forced expiratory volume in one second as percent of forced vital cavity; Hb, hemoglobin; HDL-c, HDL-cholesterol; LDL-c, LDL-cholesterol; RBC, red blood cell; T, tertile; TC, total cholesterol; TP, total protein; WBC, white blood cell.

###### 

Association between FEV~1~/FVC and adjusted dietary intake

                                                                               **Non-COPD group**   **COPD group**   ***P*-value**[¶](#tfn10-copd-5-233){ref-type="table-fn"}                                                                      
  ------------------------------------------------------------------ --------- -------------------- ---------------- ---------------------------------------------------------- ---------------- ------- ---------------- ------- ---------------- -------
  Total energy (kcal·d^−1^)                                          Model 1   2114                 1884 to 2344     2123                                                       1893 to 2354     2214    1991 to 2436     1965    1728 to 2203     0.561
                                                                     Model 2   2081                 1841 to 2321     2133                                                       1899 to 2367     2225    1999 to 2450     1977    1737 to 2217     0.723
                                                                     Model 3   2128                 1879 to 2378     2154                                                       1905 to 2403     2177    1940 to 2414     1957    1713 to 2202     0.416
  Protein (g·d^−1^)[\#](#tfn9-copd-5-233){ref-type="table-fn"}       Model 1   66.8                 59.0 to 75.6     66.2                                                       58.4 to 75.0     74.2    65.9 to 83.7     65.6    57.7 to 74.6     0.835
                                                                     Model 2   66.0                 61.3 to 71.0     65.7                                                       61.1 to 70.6     70.8    66.1 to 75.9     69.9    64.9 to 75.3     0.172
                                                                     Model 3   65.8                 61.0 to 71.1     64.6                                                       59.9 to 69.8     71.9    66.8 to 77.3     70.1    65.0 to 75.6     0.137
  Fat (g·d^−1^)[\#](#tfn9-copd-5-233){ref-type="table-fn"}           Model 1   55.9                 47.1 to 66.4     54.8                                                       46.1 to 65.1     53.1    45.0 to 62.8     50.4    42.2 to 60.2     0.422
                                                                     Model 2   55.1                 49.5 to 61.4     53.9                                                       48.5 to 59.9     50.2    45.3 to 55.6     54.8    49.1 to 61.1     0.722
                                                                     Model 3   54.9                 48.9 to 61.5     55.4                                                       49.4 to 62.1     49.2    44.1 to 54.8     54.7    48.9 to 61.3     0.674
  Carbohydrate (g· d ^−1^)                                           Model 1   292.6                260.7 to 324.5   302.2                                                      270.2 to 334.2   301.4   270.6 to 332.3   271.9   239.0 to 304.8   0.473
                                                                     Model 2   290.6                272.5 to 308.8   300.7                                                      283.0 to 318.4   288.0   270.8 to 305.1   287.9   269.5 to 306.2   0.668
                                                                     Model 3   293.1                274.1 to 312.0   296.8                                                      277.9 to 315.7   291.1   273.1 to 309.2   286.3   267.5 to 305.1   0.587
  Cholestrol (mg·d^−1^)[\#](#tfn9-copd-5-233){ref-type="table-fn"}   Model 1   264                  220 to 317       266                                                        222 to 319       346     290 to 412       276     229 to 333       0.386
                                                                     Model 2   257                  221 to 298       265                                                        229 to 306       330     287 to 380       298     256 to 346       0.072
                                                                     Model 3   253                  218 to 295       264                                                        226 to 306       336     291 to 388       297     256 to 346       0.066
  Iron (mg·d^−1^)[\#](#tfn9-copd-5-233){ref-type="table-fn"}         Model 1   6.8                  5.9 to 7.8       7.4                                                        6.4 to 8.6       8.3     7.3 to 9.6       7.1     6.2 to 8.3       0.402
                                                                     Model 2   6.6                  5.9 to 7.2       7.4                                                        6.8 to 8.2       8.0     7.3 to 8.8       7.7     7.0 to 8.5       0.020
                                                                     Model 3   6.5                  5.9 to 7.2       7.2                                                        6.5 to 8.0       8.2     7.5 to 9.0       7.8     7.0 to 8.6       0.009

**Notes:** Model 1, adjusted for age; Model 2, adjusted for age, body mass index, percent of body muscle, and total energy intake (except for analysis of total energy intake); Model 3, adjusted for all variables in Model 2 plus pack-years, pack-years squared, current-duration of smoking cessation, and history of occupational dust exposure ≥1 year;

log transformed for data analysis to improve normality, and back transformed to present data;

test for linear trend across groups was performed by treating FEV~1~/FVC as a continuous variable in multiple linear regression analysis.

**Abbreviations:** Adj, adjusted; CI, confidence interval; COPD, chronic obstructive pulmonary disease; FEV~1~/FVC, forced expiratory volume in one second as percent of forced vital cavity; T, tertile.
